Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.